Developer docs
API playgroundTry for free, no card

Search company profiles

UPyTher

Full company profile

uuid003db1t

Namestring
UPyTher
Legal namestring
UPyTher B.V.
Websiteurl
upyther.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

UPyTher B.V. is a preclinical-stage pharmaceutical company headquartered on the TU/e campus in Eindhoven, the Netherlands, developing long-acting intraperitoneal therapeutics for peritoneal carcinomatosis arising from colorectal, gastric, and ovarian cancers. The company is built around a proprietary supramolecular UPy-chemistry hydrogel platform licensed from academic research at TU/e: an injectable liquid formulation that distributes throughout the peritoneal cavity and converts in-body into a soft, elastic, self-healing drug depot providing sustained local drug release over days. Its lead product candidate UPT-211 is in nonclinical toxicity studies to enable a first-in-human trial in 2026, while a second candidate UPT-122 has proof-of-concept established in rodent models for ovarian cancer; the platform is also being extended to local intraperitoneal immunotherapy.

The company employs between 1 and 10 staff and operates as an enterprise-focused preclinical biotech, with go-to-market plans centered on future specialty hospital and oncology treatment centers via enterprise field sales once regulatory approval is secured. Revenue will be generated through product sales (specialty pharmaceuticals), with pricing to be determined post-approval. To date, UPyTher has funded operations via a June 2024 seed round (undisclosed amount) and non-dilutive grants, including an EUR 2.8 million OPZuid award for the INJECTOGELS collaboration with SupraPolix BV to scale up injectable gel production. The company has built an academic and regional partnership network spanning TU/e, SupraPolix, Maastricht University, Universiteit Gent, and the Smart BioMaterials Consortium, and added experienced biotech advisor Helmuth van Es to its Board of Advisors in July 2024.

Short descriptiontext

UPyTher B.V. is a preclinical Dutch pharmaceutical company developing a proprietary supramolecular UPy-chemistry hydrogel platform for intraperitoneal drug delivery, targeting peritoneal carcinomatosis from colorectal, gastric, and ovarian cancers with lead candidate UPT-211.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEindhoven, Netherlands
HQ citystring
Eindhoven
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intraperitoneal drug delivery, hydrogel drug formulations, peritoneal oncology therapeutics, supramolecular hydrogel platform, controlled release injectables
Industry2 codes
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Peritoneal Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Specialty Pharmaceutical Products
TypeOne Time License
Description

UPyTher is developing a pipeline of specialty-products for peritoneal oncology based on its proprietary hydrogel-drug formulation platform. The company is in preclinical development stage with products UPT-211 (colorectal cancer) and UPT-122 (ovarian cancer) in development. Revenue will be generated through product sales upon regulatory approval.

upyther.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

UPyTher develops a proprietary supramolecular UPy-chemistry based injectable hydrogel platform for intraperitoneal drug delivery in peritoneal oncology. The company's pipeline includes UPT-211 for colorectal cancer peritoneal carcinomatosis and UPT-122 for ovarian cancer, both leveraging the hydrogel platform to provide sustained local drug release in the peritoneal cavity. Products are administered as liquids that convert to soft elastic gels in vivo, forming drug depots for controlled release over days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 1.3 million new cases of peritoneal carcinomatosis worldwide each year represent addressable market
+1 more record
Product overview1 text field

UPyTher is a private pharmaceutical company developing a proprietary supramolecular hydrogel-drug formulation platform for intraperitoneal oncology applications. The core platform technology (UPy-chemistry) enables injectable hydrogels that form drug depots in the peritoneal cavity for sustained local release of therapeutics. The product portfolio includes lead candidate UPT-211 for colorectal cancer peritoneal carcinomatosis and UPT-122 for ovarian cancer, both leveraging the same hydrogel platform for intraperitoneal administration. The company is also evaluating immunomodulatory drugs for intraperitoneal immunotherapy under the peritoneal immuno-oncology program.

Product and service3 records
1UPT-211
CategoryPeritoneal Oncology Therapeutics
Description

Lead product candidate for treatment of peritoneal carcinomatosis from colorectal cancer, based on UPyTher's proprietary intraperitoneal hydrogel-drug formulation platform. Currently undergoing nonclinical toxicity studies to support a first-in-human clinical trial planned for 2026.

2UPT-122
CategoryPeritoneal Oncology Therapeutics
Description

Product candidate for treatment of ovarian cancer, leveraging the same intraperitoneal hydrogel-drug formulation platform. Proof of concept has been established in rodent models and it is currently in early nonclinical development.

3Proprietary Hydrogel-Drug Formulation Platform
CategoryDrug Delivery Platform Technology
Description

Injectable supramolecular hydrogel technology platform designed for intraperitoneal administration. The liquid formulation distributes evenly in the abdomen and forms a soft, elastic drug depot for sustained local release of therapeutics over days, addressing the limitations of intravenous-derived products for peritoneal disease.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-26
Description

Collaboration with the Dankers biomaterials research group at TU/e to identify and develop hydrogels for local immunotherapy of peritoneal cancers. Project was financially supported by the Stimuleringsfonds of the Metropoolregio Eindhoven. Developed formulations showed vastly superior safety and effectiveness in preclinical animal models.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-12
Description

Collaboration on INJECTOGELS project to scale-up production processes of injectable gels and confirm safe use as drug delivery platform for intraperitoneal therapy. Total project budget of EUR 2.8 million funded by OPZuid (European funding and Province of North Brabant).

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic research partner in the Smart BioMaterials Consortium ecosystem, contributing to peritoneal oncology research and development.

4Universiteit Gent
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Academic partner contributing to supramolecular hydrogel research for intraperitoneal drug delivery applications.

upyther.com
5Smart BioMaterials Consortium
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Consortium supporting development of biomedical materials and providing infrastructure for UPyTher's product development.

upyther.com
Strategic tierSupportingTypeTechnology or Integration
Description

Contract research organization providing nonclinical development services and laboratory testing capabilities.

Strategic tierSupportingTypeTechnology or Integration
Description

Specialized preclinical research services provider for pharmaceutical development testing.

Strategic tierSupportingTypeTechnology or Integration
Description

Technology transfer organization supporting commercialization of academic innovations in the MedTech sector.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swedish specialty pharma company developing long-acting injectable drug delivery formulations (FluidCrystal technology) for chronic disease and oncology-supportive care. Directly comparable to UPyTher in its focus on sustained-release injectable platforms that improve dosing convenience and local drug exposure.

TypeDirect peer
Description

Dutch polymer technology company developing UPy-based supramolecular materials for biomedical applications including injectable hydrogels. While also a UPyTher partner in the INJECTOGELS project, SupraPolix operates in the same supramolecular polymer drug delivery space and represents the closest technology peer.

TypeDirect peer
Description

Clinical-stage company developing polymer-based drug delivery (POZ polymer technology) for small molecules and biologics, including CNS and oncology indications. Comparable to UPyTher in its use of proprietary polymer chemistry to enable sustained-release injectable therapeutics.

TypeDirect peer
Description

U.S. specialty pharma company focused on long-acting injectable and biochronomer polymer-based therapeutics for postoperative pain, CINV, and oncology supportive care. Comparable to UPyTher in its specialty pharma focus on long-acting injectable technology for clinical and oncology-adjacent applications.

TypeEmerging player
Description

Clinical-stage company developing ultra-long-acting oral drug delivery systems designed to simplify dosing regimens. Comparable to UPyTher as a long-acting drug delivery platform company pursuing extended drug exposure, although delivery route (oral vs. intraperitoneal) and stage differ.

6DelSiTech
TypeDirect peer
Description

Finland-based developer of silica-based (SilicaMatrix) long-acting injectable drug delivery technology for parenteral administration. Comparable to UPyTher as a specialist in long-acting injectable depot formulations designed to improve drug exposure and patient compliance.

7Celsion
TypeDirect peer
Description

U.S. oncology drug delivery company developing ThermoDox, a heat-activated liposomal doxorubicin for locoregional/intraperitoneal delivery in solid tumors. Comparable to UPyTher in its focus on intraperitoneal and locoregional drug delivery for oncology, although Celsion's technology is liposome-based rather than hydrogel-based.

8Oakwood Laboratories
TypeDirect peer
Description

U.S.-based CDMO and developer specializing in long-acting injectable (LAI) formulations using biodegradable polymer microspheres. Comparable to UPyTher as a long-acting injectable specialist with deep expertise in sustained-release parenteral drug delivery.

TypeDirect peer
Description

Spanish specialty oncology company with marketed intraperitoneal-relevant products including Yondelis (trabectedin) for soft tissue sarcoma and a pipeline of marine-derived anticancer agents. Comparable to UPyTher as a specialty oncology company developing therapeutics for indications where intraperitoneal delivery is clinically relevant.

TypeBroad incumbent
Description

Following its acquisition of BTG, Boston Scientific operates a significant interventional oncology franchise that includes locoregional therapies for liver and other cancers, overlapping with UPyTher's regional cancer delivery space. Included as a broad incumbent whose interventional oncology portfolio represents both competitive context and potential partnership interest.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

UPyTher

Peritoneal Oncology Therapeuticsupyther.com

UPyTher B.V. is a preclinical Dutch pharmaceutical company developing a proprietary supramolecular UPy-chemistry hydrogel platform for intraperitoneal drug delivery, targeting peritoneal carcinomatosis from colorectal, gastric, and ovarian cancers with lead candidate UPT-211.

What UPyTher does

UPyTher B.V. is a preclinical-stage pharmaceutical company headquartered on the TU/e campus in Eindhoven, the Netherlands, developing long-acting intraperitoneal therapeutics for peritoneal carcinomatosis arising from colorectal, gastric, and ovarian cancers. The company is built around a proprietary supramolecular UPy-chemistry hydrogel platform licensed from academic research at TU/e: an injectable liquid formulation that distributes throughout the peritoneal cavity and converts in-body into a soft, elastic, self-healing drug depot providing sustained local drug release over days. Its lead product candidate UPT-211 is in nonclinical toxicity studies to enable a first-in-human trial in 2026, while a second candidate UPT-122 has proof-of-concept established in rodent models for ovarian cancer; the platform is also being extended to local intraperitoneal immunotherapy.

The company employs between 1 and 10 staff and operates as an enterprise-focused preclinical biotech, with go-to-market plans centered on future specialty hospital and oncology treatment centers via enterprise field sales once regulatory approval is secured. Revenue will be generated through product sales (specialty pharmaceuticals), with pricing to be determined post-approval. To date, UPyTher has funded operations via a June 2024 seed round (undisclosed amount) and non-dilutive grants, including an EUR 2.8 million OPZuid award for the INJECTOGELS collaboration with SupraPolix BV to scale up injectable gel production. The company has built an academic and regional partnership network spanning TU/e, SupraPolix, Maastricht University, Universiteit Gent, and the Smart BioMaterials Consortium, and added experienced biotech advisor Helmuth van Es to its Board of Advisors in July 2024.

UPyTher firmographics

Firmographics
Name
UPyTher
Legal name
UPyTher B.V.
Website
https://upyther.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
UPyTher B.V. is a preclinical Dutch pharmaceutical company developing a proprietary supramolecular UPy-chemistry hydrogel platform for intraperitoneal drug delivery, targeting peritoneal carcinomatosis from colorectal, gastric, and ovarian cancers with lead candidate UPT-211.
Ownership category
akta.pro rank

UPyTher industry classification

Industry
Product category
Peritoneal Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Intraperitoneal drug delivery
  • Hydrogel drug formulations
  • Peritoneal oncology therapeutics
  • Supramolecular hydrogel platform
  • Controlled release injectables

Where UPyTher is headquartered

Location

Headquarters

HQ city
Eindhoven
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

UPyTher business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Specialty Pharmaceutical Products: UPyTher is developing a pipeline of specialty-products for peritoneal oncology based on its proprietary hydrogel-drug formulation platform. The company is in preclinical development stage with products UPT-211 (colorectal cancer) and UPT-122 (ovarian cancer) in development. Revenue will be generated through product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

UPyTher product offering

Product offering

Core offering

UPyTher develops a proprietary supramolecular UPy-chemistry based injectable hydrogel platform for intraperitoneal drug delivery in peritoneal oncology. The company's pipeline includes UPT-211 for colorectal cancer peritoneal carcinomatosis and UPT-122 for ovarian cancer, both leveraging the hydrogel platform to provide sustained local drug release in the peritoneal cavity. Products are administered as liquids that convert to soft elastic gels in vivo, forming drug depots for controlled release over days.

Product overview

UPyTher is a private pharmaceutical company developing a proprietary supramolecular hydrogel-drug formulation platform for intraperitoneal oncology applications. The core platform technology (UPy-chemistry) enables injectable hydrogels that form drug depots in the peritoneal cavity for sustained local release of therapeutics. The product portfolio includes lead candidate UPT-211 for colorectal cancer peritoneal carcinomatosis and UPT-122 for ovarian cancer, both leveraging the same hydrogel platform for intraperitoneal administration. The company is also evaluating immunomodulatory drugs for intraperitoneal immunotherapy under the peritoneal immuno-oncology program.

Differentiator

Problem solved

Functional benefit

Products and services

  • UPT-211 Lead product candidate for treatment of peritoneal carcinomatosis from colorectal cancer, based on UPyTher's proprietary intraperitoneal hydrogel-drug formulation platform. Currently undergoing nonclinical toxicity studies to support a first-in-human clinical trial planned for 2026.
  • UPT-122 Product candidate for treatment of ovarian cancer, leveraging the same intraperitoneal hydrogel-drug formulation platform. Proof of concept has been established in rodent models and it is currently in early nonclinical development.
  • Proprietary Hydrogel-Drug Formulation Platform Injectable supramolecular hydrogel technology platform designed for intraperitoneal administration. The liquid formulation distributes evenly in the abdomen and forms a soft, elastic drug depot for sustained local release of therapeutics over days, addressing the limitations of intravenous-derived products for peritoneal disease.

Quantifiable outcome

  • 1.3 million new cases of peritoneal carcinomatosis worldwide each year represent addressable market
  • +1 more outcomes

Companies that use UPyTher

Customer profile

Segments1 record

Ideal customer profiles2 records

UPyTher technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

UPyTher partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and supporting.

  • Eindhoven University of Technology (TU/e)coreStrategic or Co-development Partner · 26 November 2024Collaboration with the Dankers biomaterials research group at TU/e to identify and develop hydrogels for local immunotherapy of peritoneal cancers. Project was financially supported by the Stimuleringsfonds of the Metropoolregio Eindhoven. Developed formulations showed vastly superior safety and effectiveness in preclinical animal models.
  • SupraPolix BVcoreStrategic or Co-development Partner · 12 April 2024Collaboration on INJECTOGELS project to scale-up production processes of injectable gels and confirm safe use as drug delivery platform for intraperitoneal therapy. Total project budget of EUR 2.8 million funded by OPZuid (European funding and Province of North Brabant).
  • Maastricht UniversitysupportingStrategic or Co-development PartnerAcademic research partner in the Smart BioMaterials Consortium ecosystem, contributing to peritoneal oncology research and development.
  • Universiteit GentsupportingStrategic or Co-development PartnerAcademic partner contributing to supramolecular hydrogel research for intraperitoneal drug delivery applications.
  • Smart BioMaterials ConsortiumsupportingStrategic or Co-development PartnerConsortium supporting development of biomedical materials and providing infrastructure for UPyTher's product development.
  • InnoSersupportingTechnology or IntegrationContract research organization providing nonclinical development services and laboratory testing capabilities.
  • SpecipigsupportingTechnology or IntegrationSpecialized preclinical research services provider for pharmaceutical development testing.
  • Tech Transfer Team (TTT)supportingTechnology or IntegrationTechnology transfer organization supporting commercialization of academic innovations in the MedTech sector.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

UPyTher competitors and assessment

Company assessment

Direct peers

  • Camurus: Swedish specialty pharma company developing long-acting injectable drug delivery formulations (FluidCrystal technology) for chronic disease and oncology-supportive care. Directly comparable to UPyTher in its focus on sustained-release injectable platforms that improve dosing convenience and local drug exposure.
  • SupraPolix: Dutch polymer technology company developing UPy-based supramolecular materials for biomedical applications including injectable hydrogels. While also a UPyTher partner in the INJECTOGELS project, SupraPolix operates in the same supramolecular polymer drug delivery space and represents the closest technology peer.
  • Serina Therapeutics: Clinical-stage company developing polymer-based drug delivery (POZ polymer technology) for small molecules and biologics, including CNS and oncology indications. Comparable to UPyTher in its use of proprietary polymer chemistry to enable sustained-release injectable therapeutics.
  • Heron Therapeutics: U.S. specialty pharma company focused on long-acting injectable and biochronomer polymer-based therapeutics for postoperative pain, CINV, and oncology supportive care. Comparable to UPyTher in its specialty pharma focus on long-acting injectable technology for clinical and oncology-adjacent applications.
  • DelSiTech: Finland-based developer of silica-based (SilicaMatrix) long-acting injectable drug delivery technology for parenteral administration. Comparable to UPyTher as a specialist in long-acting injectable depot formulations designed to improve drug exposure and patient compliance.
  • Celsion: U.S. oncology drug delivery company developing ThermoDox, a heat-activated liposomal doxorubicin for locoregional/intraperitoneal delivery in solid tumors. Comparable to UPyTher in its focus on intraperitoneal and locoregional drug delivery for oncology, although Celsion's technology is liposome-based rather than hydrogel-based.
  • Oakwood Laboratories: U.S.-based CDMO and developer specializing in long-acting injectable (LAI) formulations using biodegradable polymer microspheres. Comparable to UPyTher as a long-acting injectable specialist with deep expertise in sustained-release parenteral drug delivery.
  • PharmaMar: Spanish specialty oncology company with marketed intraperitoneal-relevant products including Yondelis (trabectedin) for soft tissue sarcoma and a pipeline of marine-derived anticancer agents. Comparable to UPyTher as a specialty oncology company developing therapeutics for indications where intraperitoneal delivery is clinically relevant.

Emerging players

  • Lyndra Therapeutics: Clinical-stage company developing ultra-long-acting oral drug delivery systems designed to simplify dosing regimens. Comparable to UPyTher as a long-acting drug delivery platform company pursuing extended drug exposure, although delivery route (oral vs. intraperitoneal) and stage differ.

Broad incumbents

  • Boston Scientific (BTG interventional oncology): Following its acquisition of BTG, Boston Scientific operates a significant interventional oncology franchise that includes locoregional therapies for liver and other cancers, overlapping with UPyTher's regional cancer delivery space. Included as a broad incumbent whose interventional oncology portfolio represents both competitive context and potential partnership interest.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

UPyTher social profiles

Digital presence

UPyTher financial estimates

Financial estimate

Revenue estimate

Valuation estimate

UPyTher leadership team

Management profile

Number of profiles

Profiles13 records

UPyTher funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

UPyTher M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UPyTher

What does UPyTher do?

UPyTher develops a proprietary supramolecular UPy-chemistry based injectable hydrogel platform for intraperitoneal drug delivery in peritoneal oncology. The company's pipeline includes UPT-211 for colorectal cancer peritoneal carcinomatosis and UPT-122 for ovarian cancer, both leveraging the hydrogel platform to provide sustained local drug release in the peritoneal cavity. Products are administered as liquids that convert to soft elastic gels in vivo, forming drug depots for controlled release over days.

Is UPyTher a public or private company?

UPyTher is a private company. It is classified as venture growth investor backed and is currently operating.

When was UPyTher founded?

UPyTher was founded in 2020. It employs 1 to 10 people.

Where is UPyTher based?

UPyTher is headquartered in Eindhoven, Netherlands, in the Europe region.

How does UPyTher make money?

One revenue line is on record: specialty Pharmaceutical Products.

Who are UPyTher's main competitors?

Direct peers on record are Camurus, SupraPolix, Serina Therapeutics, Heron Therapeutics, DelSiTech, Celsion, Oakwood Laboratories and PharmaMar. Lyndra Therapeutics is listed as an emerging player. Boston Scientific (BTG interventional oncology) is listed as a broad incumbent.

Does UPyTher have an API?

No public API is recorded for UPyTher.

What industry is UPyTher in?

UPyTher's product category is Peritoneal Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales